This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Tumor-targeting bispecific antibodies	<p>A study in cell culture and in mice suggests that antibodies with affinity for both tumor antigens and cytotoxic effector cells could help treat lymphatic cancers. In cell culture, a bispecific antibody was better at triggering tumor cell death than control antibodies that bound only tumor antigen. In a mouse model of B cell lymphoma (BCL), the bispecific antibody lowered tumor cell titers and improved survival compared with mock control. Next steps include pharmacokinetic and pharmacodynamic studies.</p> <p>SciBX 3(20); doi:10.1038/scibx.2010.632 Published online May 20, 2010</p>	<p>Patent pending; available for licensing and partnering from MacroGenics Inc.</p> <p>Contact: Scott Koenig, MacroGenics Inc., Rockville, Md. e-mail: koenigs@macrogenics.com</p>	<p>Johnson, S. <i>et al. J. Mol. Biol.</i>; published online April 9, 2010; doi:10.1016/j.jmb.2010.04.001</p> <p>Contact: Syd Johnson, MacroGenics Inc., Rockville, Md. e-mail: johnsons@macrogenics.com</p>